IL33 and gastric cancer: These data suggest that chronic H. pylori-mediated inhibition of gastric IL33 may be a key event in GC progression, preventing the induction of Th2 immunity and dysregulating the local immune response to Th1/Th17 cells, thereby exacerbating carcinogenesis.